This Glasgow Biotech Just Raised $46M to Fight a Silent Kidney Disease

Jan de Vries · 2026-08-07

When a biotech company secures a massive funding round, it's easy to skim past the headline. But the story behind Mironid's latest raise is worth a closer look—especially if you care about the future of rare disease treatment. Mironid, a Glasgow-based biopharmaceutical company, just closed a $46 million Series B financing round. The money will push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. That's a big deal for the roughly 12 million people worldwide living with this condition. ### What Is ADPKD, and Why Should You Care? ADPKD is the most common hereditary kidney disorder. It's caused by mutations in the PKD1 or PKD2 genes, which lead to uncontrolled growth of fluid-filled cysts in the kidneys. Over time, these cysts crowd out healthy tissue, and about 50% of patients develop kidney failure by age 60. Neil Wilkie, CEO of Mironid, put it plainly: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD." The current treatment landscape isn't great. Existing therapies can slow progression, but they come with side effects and don't work for everyone. That's where Mironid's approach stands out. ### The Science Behind the Funding Mironid's lead candidate is a first-in-class "LoAc" small molecule. Instead of just managing symptoms, it directly targets cyclic AMP (cAMP)—a cellular signal that's active at every stage of the disease, from initiation to end-stage. cAMP drives both cell proliferation and fluid secretion within the cysts. Preclinical data shows significant efficacy and a favorable safety profile. The drug reduced cyst number and kidney volume in studies. Mironid believes that by preventing new cyst formation and arresting growth of existing ones, its approach could offer a more durable treatment with fewer side effects. ### A Decade in the Making Mironid spun out of the University of Strathclyde and Heriot-Watt University in 2015. It builds on more than three decades of research into PDE biology by Professor Miles Houslay. The company focuses on degenerative and rare genetic kidney diseases, plus major inflammatory diseases and cancer. Beyond ADPKD, Mironid's pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways tied to disease progression. ### Who's Backing This? The round was led by Scottish National Investment Bank, joining a syndicate of existing backers: - Roche Venture Fund - Epidarex Capital - Sofinnova Partners - BioGeneration Ventures - University of Strathclyde Paul Callaghan, Investment Director at the Scottish National Investment Bank, said: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease. We are pleased to join a committed group of investors to support the company through this critical stage of development." ### What's Next? The fresh capital follows an earlier Series A extension round, bringing Mironid's total funding since inception to about $46.8 million (€40.8 million). The company will use the proceeds to advance clinical development of its lead candidate. If the drug performs well in trials, it could genuinely transform how we treat ADPKD. For now, the biotech world is watching—and the patients waiting for better options are, too.